Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the company. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $10.57.

ZIOP has been the topic of several recent research reports. Mizuho reaffirmed a “neutral” rating and issued a $5.00 price target (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Griffin Securities reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ziopharm Oncology in a report on Tuesday, June 7th. Wells Fargo & Co. raised shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Raymond James Financial Inc. initiated coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Finally, Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Wednesday, July 27th.

Ziopharm Oncology (NASDAQ:ZIOP) traded up 3.00% during mid-day trading on Tuesday, reaching $5.83. 1,969,417 shares of the company traded hands. The stock’s market capitalization is $760.79 million. The stock has a 50-day moving average of $5.32 and a 200 day moving average of $6.57. Ziopharm Oncology has a 52-week low of $4.45 and a 52-week high of $14.93.

Ziopharm Oncology (NASDAQ:ZIOP) last issued its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.90. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The company’s quarterly revenue was up 525.0% compared to the same quarter last year. Equities research analysts expect that Ziopharm Oncology will post ($1.34) earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ZIOP. Fox Run Management L.L.C. purchased a new position in shares of Ziopharm Oncology during the second quarter valued at about $133,000. Stratos Wealth Partners LTD. purchased a new position in shares of Ziopharm Oncology during the first quarter valued at about $102,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock valued at $22,601,000 after buying an additional 17,982 shares during the last quarter. Commonwealth Equity Services Inc increased its position in shares of Ziopharm Oncology by 4.7% in the first quarter. Commonwealth Equity Services Inc now owns 46,575 shares of the biotechnology company’s stock valued at $346,000 after buying an additional 2,109 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Ziopharm Oncology by 4.5% in the first quarter. TIAA CREF Investment Management LLC now owns 447,313 shares of the biotechnology company’s stock valued at $3,319,000 after buying an additional 19,211 shares during the last quarter. 44.95% of the stock is currently owned by institutional investors and hedge funds.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

5 Day Chart for NASDAQ:ZIOP

Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.